Peter Radovich
CIK: 0001650131
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (25 total)
- Oct 20, 2026MBX
MBX Biosciences, Inc.
Award(A)DirectStock option (right to buy)
18.2K shares- - Jun 5, 2026MIRM
Mirum Pharmaceuticals, Inc.
Exercise(M)Direct17K shares at avg. $19.19$326K - Mar 16, 2026MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct16.5K shares at avg. $91.98$1.5M - Mar 15, 2026MIRM
Mirum Pharmaceuticals, Inc.
Exercise(M)Direct7.2K shares- - Mar 15, 2026MIRM
Mirum Pharmaceuticals, Inc.
Exercise(M)Direct23K shares- - Mar 6, 2026MIRM
Mirum Pharmaceuticals, Inc.
Exercise(M)Direct5.9K shares at avg. $15.87$94K - Feb 2, 2026MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct2.6K shares at avg. $103.30$272K - Jan 28, 2026MIRM
Mirum Pharmaceuticals, Inc.
Award(A)DirectPerformance Restricted Stock Units
34.5K shares- - Jan 28, 2026MIRM
Mirum Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
16.3K shares- - Jan 28, 2026MIRM
Mirum Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
25.1K shares- - Jan 26, 2026MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct3.1K shares at avg. $96.19$302K - Jan 23, 2026MIRM
Mirum Pharmaceuticals, Inc.
Exercise(M)Direct5.8K shares- - Jan 22, 2026MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct2.4K shares at avg. $93.33$222K - Jan 21, 2026MIRM
Mirum Pharmaceuticals, Inc.
Exercise(M)Direct4.2K shares- - Mar 17, 2025MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct7.9K shares at avg. $44.21$348K - Mar 15, 2025MIRM
Mirum Pharmaceuticals, Inc.
Exercise(M)Direct14.4K shares- - Mar 4, 2025MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct13.7K shares at avg. $45.57$623K - Mar 4, 2025MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct1.2K shares at avg. $45.74$53K - Feb 3, 2025MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct2.6K shares at avg. $48.22$127K - Jan 24, 2025MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct3.2K shares at avg. $47.92$152K - Jan 23, 2025MIRM
Mirum Pharmaceuticals, Inc.
Exercise(M)Direct5.8K shares- - Jan 21, 2025MIRM
Mirum Pharmaceuticals, Inc.
Award(A)DirectPerformance Restricted Stock Units
21.7K shares- - Jan 21, 2025MIRM
Mirum Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
50K shares- - Jan 21, 2025MIRM
Mirum Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
12.5K shares- - Jan 7, 2025MIRM
Mirum Pharmaceuticals, Inc.
Sale(S)Direct2K shares at avg. $42.82$86K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 20, 2026 |  MBX MBX Biosciences, Inc. | Award(A) Stock option (right to buy) | 18,200 | - | - | Direct |
| Jun 5, 2026 |  MIRM Mirum Pharmaceuticals, Inc. | Exercise(M) | 16,988 | $19.19 | $326,000 | Direct |
| Mar 16, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 16,515 | $91.98 | $1,519,015 | Direct |
| Mar 15, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Exercise(M) | 7,220 | - | $0 | Direct |
| Mar 15, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Exercise(M) | 23,000 | - | $0 | Direct |
| Mar 6, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Exercise(M) | 5,912 | $15.87 | $93,823 | Direct |
| Feb 2, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 2,631 | $103.30 | $271,792 | Direct |
| Jan 28, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Award(A) Performance Restricted Stock Units | 34,500 | - | - | Direct |
| Jan 28, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 16,280 | - | - | Direct |
| Jan 28, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 25,120 | - | - | Direct |
| Jan 26, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 3,143 | $96.19 | $302,331 | Direct |
| Jan 23, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Exercise(M) | 5,750 | - | $0 | Direct |
| Jan 22, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 2,382 | $93.33 | $222,301 | Direct |
| Jan 21, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Exercise(M) | 4,167 | - | $0 | Direct |
| Mar 17, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 7,879 | $44.21 | $348,364 | Direct |
| Mar 15, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Exercise(M) | 14,440 | - | - | Direct |
| Mar 4, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 13,681 | $45.57 | $623,458 | Direct |
| Mar 4, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 1,169 | $45.74 | $53,470 | Direct |
| Feb 3, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 2,627 | $48.22 | $126,681 | Direct |
| Jan 24, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 3,177 | $47.92 | $152,256 | Direct |
| Jan 23, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Exercise(M) | 5,750 | - | $0 | Direct |
| Jan 21, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Award(A) Performance Restricted Stock Units | 21,660 | - | - | Direct |
| Jan 21, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 50,000 | - | - | Direct |
| Jan 21, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 12,500 | - | - | Direct |
| Jan 7, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Sale(S) | 1,998 | $42.82 | $85,545 | Direct |
1-25 of 25 transactions
About Radovich Peter
Radovich Peter (SEC CIK 0001650131) files insider reports with the SEC as Director of MBX Biosciences, Inc. (MBX) and PRESIDENT AND COO of Mirum Pharmaceuticals, Inc. (MIRM).
Signal8 holds 15 ownership filings by Radovich Peter (1 Form 3, 14 Form 4), filed between Jan 8, 2025 and Oct 22, 2026. Those filings report 25 transactions, from Jan 7, 2025 to Oct 20, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Radovich Peter's filings is in CARMEL, IN.
Recent filings by Radovich Peter
- Oct 20, 2026: Grant or award of MBX derivative securities (Form 4, code A).
- Jun 5, 2026: Option exercise of MIRM shares (Form 4, code M).
- Mar 16, 2026: Open-market sale of MIRM shares (Form 4, code S).
- Mar 15, 2026: Option exercises of MIRM shares (2 lines, Form 4, code M).
- Mar 6, 2026: Option exercise of MIRM shares (Form 4, code M).
Other insiders filing for MBX Biosciences, Inc. (MBX)
- Azoulay Salomon, Chief Medical Officer
- Smither John W, Chief Financial Officer
- Hoerter Steven L., President and CEO
- Mathers Edward T, Director
- Pescovitz Ora H., Director
- Heron Patrick J, Director